Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol-Reference-Cited by-同舟云学术

Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol

Published:2002-10 Issue:8 Volume:74 Page:1136-1141
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:Transplantation

Author:

Baran David A.,Galin Ira,Sandler David,Segura Leal,Cheng Judy,Courtney Mary C.,Correa Rhodora,Chan Ming,Fallon John T.,Spielvogel David,Lansman Steven L.,Gass Alan L.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference13 articles.

1. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus11This study was sponsored by a grant from Fujisawa USA, Deerfield, Illinois.22The authors were working on behalf of the Tacrolimus US Heart Transplant Multicenter Study Group. Other members of the Study Group included (principal investigator listed first): UTAH Cardiac Transplant Program, Salt Lake City, Utah: David O. Taylor, MD, Dale G. Renlund, MD, Abdallah G. Kfoury, MD; St. Luke’s Episcopal Hospital/Texas Heart Institute, Houston, Texas: O. H. Frazier, MD, Branislav Radovancevic, MD, Edward K. Massin, MD; University of Wisconsin Hospitals and Clinics, Madison, Wisconsin: Robert M. Mentzer, Jr., MD, Charles C. Canver, MD, Robert B. Love, MD; Ochsner Medical Foundation, New Orleans, Louisiana: Frank W. Smart, MD, Hector O. Ventura, MD, Dwight D. Stapleton, MD, Mandeep Mehra, MD; University of Southern California, Los Angeles, California: Mark L. Barr, MD, Vaugh A. Starnes, MD; Medical College of Virginia, Richmond, Virginia: David E. Tolman, MD, Albert Guerraty, MD, David Salter, MD; Cleveland Clinic Foundation, Cleveland, Ohio: James B. Young, MD; Data Management and Statistical Coordinating Center-The EMMES Corporation, Potomac, Maryland: Paul VanVeldhuisen, MS, Anne Lindblad, PhD, Anita Yaffe, MSN, MPH.

2. Factors Affecting the Pharmacokinetics of Tacrolimus in the First Year After Renal Transplantation

3. RELATIONSHIP OF FK506 WHOLE BLOOD CONCENTRATIONS AND EFFICACY AND TOXICITY AFTER LIVER AND KIDNEY TRANSPLANTATION

4. Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tacrolimus Therapy in Adult Heart Transplant Recipients: Evaluation of a Bayesian Forecasting Software;Therapeutic Drug Monitoring;2021-12

2. Association of tacrolimus time‐to‐therapeutic range on renal dysfunction and acute cellular rejection after orthotopic heart transplantation in a high use basiliximab population;Clinical Transplantation;2021-11-28

3. Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review;Transplantation Reviews;2021-04

4. Evaluation of Cyclosporine and Tacrolimus Dose Changes During Post-transplantation Period and Their Association with Endomyocardial Biopsy Grading;Multidisciplinary Cardiovascular Annals;2021-01-11

5. Association Between Time‐in‐Therapeutic Tacrolimus Range and Early Rejection After Heart Transplant;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2019-04-02